AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36403926 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of hyperreflective foci (HRF) and SDD
Number of subjects: 158
Study 36404213 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic pulses with interphase gap of 0 μs
Number of subjects: 9
Study 36404213 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic pulses with interphase gaps of 10, 20, 50, and 100 μs
Number of subjects: 9
Study 36404274 — intervention group
Group type: EXPERIMENTAL
Intervention: PDAC-DM
Number of subjects: 165
Study 36404274 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-DM
Number of subjects: 165
Study 36404274 — intervention group
Group type: COMPARATOR
Intervention: T2DM
Number of subjects: 165
Study 36404384 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 9
Study 36404403 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva-based SARS-CoV-2 screening testing
Number of subjects: 31
Study 36404403 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening testing
Number of subjects: 31
Study 36404469 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D treatment, specific dosage and duration not mentioned
Number of subjects: 0
Study 36404469 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 36404528 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO prior to SRS
Number of subjects: 38
Study 36404528 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 36404708 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor D (FD) inhibitor, danicopan
Number of subjects: 29
Study 36404730 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle program; details on dosage and duration not available
Number of subjects: 0
Study 36405821 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of corticosteroid therapy (Group A)
Number of subjects: 33
Study 36405821 — intervention group
Group type: COMPARATOR
Intervention: 12-14 weeks of standard therapy (Group B)
Number of subjects: 33
Study 36405923 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy (MDMA-AT)
Number of subjects: 32
Study 36406365 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum NLRP3 protein level at the end of the operation
Number of subjects: 75
Study 36406365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive dysfunction
Number of subjects: 75
Study 36406365 — intervention group
Group type: EXPERIMENTAL
Intervention: NLRP3 protein levels
Number of subjects: 75
Study 36406365 — intervention group
Group type: EXPERIMENTAL
Intervention: PND incidence
Number of subjects: 75
Study 36406365 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum NLRP3 protein level, old age
Number of subjects: 75
Study 36406817 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous sulfate 325 mg twice daily for 12 months
Number of subjects: 16
Study 36407071 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvascular disease
Number of subjects: 8856
Study 36407071 — intervention group
Group type: COMPARATOR
Intervention: CAD only
Number of subjects: 8856
Study 36407294 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD diagnosis and assessment through validated questionnaires
Number of subjects: 219
Study 36407294 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for psychosocial status
Number of subjects: 219
Study 36407519 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-/post-nutrient timing
Number of subjects: 64
Study 36407519 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 36407523 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal adiposity (measured by BMI)
Number of subjects: 223
Study 36407523 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal adiposity (overweight mothers)
Number of subjects: 223
Study 36407522 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day fast followed by an 11-week plant-based diet (PBD)
Number of subjects: 53
Study 36407522 — intervention group
Group type: COMPARATOR
Intervention: 12-week standard DGE diet
Number of subjects: 53
Study 36408119 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Moment intervention
Number of subjects: 292
Study 36408118 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief mindfulness-based intervention (MBI) named 'STOP touching your face'
Number of subjects: 0
Study 36408118 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list)
Number of subjects: 0
Study 36408511 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on clinical data from the DIRECT-MT trial
Number of subjects: 656
Study 36408511 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAS-LVO group (45 cases)
Number of subjects: 656
Study 36408511 — intervention group
Group type: COMPARATOR
Intervention: Non-ICAS-LVO group (611 cases)
Number of subjects: 656
Study 36408587 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotralstat
Number of subjects: 0
Study 36408587 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 36408618 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×MVA
Number of subjects: 745
Study 36408618 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×MVA
Number of subjects: 745
Study 36408618 — intervention group
Group type: EXPERIMENTAL
Intervention: HSPX
Number of subjects: 745
Study 36408618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 745
Study 36408866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function test (PFT)
Number of subjects: 25
Study 36408866 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Impairment Scale (TIS)
Number of subjects: 25
Study 36408866 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index (BI)
Number of subjects: 25
Study 36408866 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory muscle strength
Number of subjects: 25
Study 36408876 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate (PCC)
Number of subjects: 4993
Study 36408923 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation treatment
Number of subjects: 2019
Study 36409100 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Emotion Awareness + Cognitive Reappraisal (MEA + CR)
Number of subjects: 234
Study 36409100 — intervention group
Group type: COMPARATOR
Intervention: Mindful Emotion Awareness (MEA)
Number of subjects: 234
Study 36409100 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Reappraisal (CR)
Number of subjects: 234
Study 36409226 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related group cognitive behavioral therapy plus vocational services (WCBT+VSAU)
Number of subjects: 250
Study 36409226 — intervention group
Group type: COMPARATOR
Intervention: Vocational services only (VSAU-alone)
Number of subjects: 250
Study 36409282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose extended half-life (EHL) FVIII prophylaxis with PK-based adjustment
Number of subjects: 15
Study 36409282 — intervention group
Group type: COMPARATOR
Intervention: Low-dose standard half-life (SHL) FVIII prophylaxis
Number of subjects: 15
Study 36409354 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tolerable doses of evidence-based medications
Number of subjects: 224
Study 36409541 — intervention group
Group type: EXPERIMENTAL
Intervention: PlusCare digital app for HIV case management
Number of subjects: 45
Study 36409543 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Milk Composition
Number of subjects: 0
Study 36409543 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Growth
Number of subjects: 0
Study 36409612 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 59
Study 36409676 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Work Intervention for Palliative Care
Number of subjects: 0
Study 36409740 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+ men
Number of subjects: 481
Study 36409740 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV+ women
Number of subjects: 481
Study 36409740 — intervention group
Group type: COMPARATOR
Intervention: HIV- participants
Number of subjects: 481
Study 36409740 — intervention group
Group type: EXPERIMENTAL
Intervention: PWH
Number of subjects: 481
Study 36409773 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic responses to available and new compounds against Trypanosoma cruzi infection.
Number of subjects: 0
Study 36409773 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative-PCR data obtained from blood samples collected regularly over a year.
Number of subjects: 0
Study 36409773 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorization of individuals based on distinct parasitological status.
Number of subjects: 0
Study 36409927 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular flushing during oocyte retrieval
Number of subjects: 1643
Study 36409927 — intervention group
Group type: COMPARATOR
Intervention: Aspiration alone
Number of subjects: 1643
Study 36409958 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE mobile app intervention
Number of subjects: 800
Study 36409958 — intervention group
Group type: COMPARATOR
Intervention: Active comparison control app
Number of subjects: 800
Study 36410013 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging measures including multimodal Magnetic Resonance Imaging (MRI) and Spectroscopy (MRS) scans of the brain and spinal cord, clinical, cognitive, mood and speech assessments, blood sample collection.
Number of subjects: 200
Study 36410013 — intervention group
Group type: COMPARATOR
Intervention: Control group (104 participants) matched for age, sex, handedness, and years of education.
Number of subjects: 200
Study 36410034 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy (TAT)
Number of subjects: 647
Study 36410034 — intervention group
Group type: COMPARATOR
Intervention: Dual antithrombotic therapy (DAT)
Number of subjects: 647
Study 36410152 — intervention group
Group type: EXPERIMENTAL
Intervention: MDZ-NS 5 mg administered for seizure clusters, with a second dose possible within 10 minutes if seizures did not terminate or recurred within 6 hours.
Number of subjects: 175
Study 36410152 — intervention group
Group type: EXPERIMENTAL
Intervention: MDZ-NS
Number of subjects: 175
Study 36410207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pertuzumab plus trastuzumab (PH IV)
Number of subjects: 4772
Study 36410207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC)
Number of subjects: 4772
Study 36410339 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + EX
Number of subjects: 44
Study 36410339 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 44
Study 36410441 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable SAPIEN-3 Ultra
Number of subjects: 440
Study 36410441 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding EVOLUT PRO+
Number of subjects: 440
Study 36410441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 440
Study 36410605 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteroposterior (AP) pacer pad position
Number of subjects: 20
Study 36410605 — intervention group
Group type: COMPARATOR
Intervention: Anterolateral (AL) pacer pad position
Number of subjects: 20
Study 36410797 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRV-B) intervention using a Polar chest strap device linked to the Elite HRV phone application for 4 weeks, with two 10-minute sessions daily for at least 5 days a week.
Number of subjects: 30
Study 36410797 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRV-B) intervention
Number of subjects: 30
Study 36410805 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental menthol VLNCs
Number of subjects: 172
Study 36410805 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental non-menthol VLNCs
Number of subjects: 172
Study 36410805 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed product standards
Number of subjects: 172
Study 36410804 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistell AST
Number of subjects: 300
Study 36410808 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual follow-up by GP with clinical and laboratory data collection and lifestyle questionnaires at inclusion, 2-year, and 5-year follow-ups.
Number of subjects: 0
Study 36410913 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigator-Initiated Trials (IITs)
Number of subjects: 0
Study 36410913 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 36411033 — intervention group
Group type: EXPERIMENTAL
Intervention: Gepotidacin 3000 mg oral doses administered 10-12 hours apart
Number of subjects: 0
Study 36411081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets
Number of subjects: 57
Study 36411150 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 89
Study 36411203 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva-based miRNA signature for endometriosis-associated infertility
Number of subjects: 200
Study 36411203 — intervention group
Group type: COMPARATOR
Intervention: Saliva samples from patients diagnosed with endometriosis
Number of subjects: 200
Study 36411217 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy (HD) diet (4 servings/day for six weeks)
Number of subjects: 10
Study 36411267 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (tixagevimab/cilgavimab) 300 mg (1.5 mL intramuscular injection)
Number of subjects: 1121
Study 36411267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1121
Study 36411966 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal Growth Restriction (FGR) fetuses
Number of subjects: 36
Study 36411966 — intervention group
Group type: COMPARATOR
Intervention: Healthy fetuses with birthweights between the 10th and the 90th percentile (average for gestational age [AGA])
Number of subjects: 36
Study 36412064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and vorinostat
Number of subjects: 50
Study 36412069 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontline worker (FLW) visits
Number of subjects: 0
Study 36412069 — intervention group
Group type: EXPERIMENTAL
Intervention: FLW visits
Number of subjects: 0
Study 36412069 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with FLW visits
Number of subjects: 0
Study 36412069 — intervention group
Group type: EXPERIMENTAL
Intervention: Development index
Number of subjects: 0
Study 36412069 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of scheduled caste or tribe
Number of subjects: 0
Study 36412095 — intervention group
Group type: EXPERIMENTAL
Intervention: peg-interferon beta-1a
Number of subjects: 0
Study 36412095 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 36412229 — intervention group
Group type: EXPERIMENTAL
Intervention: Man Therapy (MT)
Number of subjects: 0
Study 36412229 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 36412278 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening testing program in Durham schools
Number of subjects: 1600
Study 36412278 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening testing program in Kansas City schools
Number of subjects: 1600
Study 36412278 — intervention group
Group type: COMPARATOR
Intervention: Community positivity rates
Number of subjects: 1600
Study 36412504 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTI_sh (multidisciplinary lifestyle intervention)
Number of subjects: 74
Study 36412692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular Bone Allograft (CBA)
Number of subjects: 201
Study 36412692 — intervention group
Group type: EXPERIMENTAL
Intervention: CBA
Number of subjects: 201
Study 36412798 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline Catheters
Number of subjects: 44
Study 36412798 — intervention group
Group type: COMPARATOR
Intervention: Peripheral Intravenous Catheters (PIVC)
Number of subjects: 44
Study 36413013 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0
Study 36413013 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36413080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg
Number of subjects: 1531
Study 36413080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1531
Study 36413080 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg
Number of subjects: 1531
Study 36413080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg in open-label extensions (OLEs)
Number of subjects: 1531
Study 36413141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined onvansertib and abiraterone
Number of subjects: 0
Study 36413141 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone
Number of subjects: 0
Study 36413141 — intervention group
Group type: COMPARATOR
Intervention: Plk1 inhibition (onvansertib)
Number of subjects: 0
Study 36413205 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity meeting current recommendations
Number of subjects: 445
Study 36413205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration meeting current recommendations
Number of subjects: 445
Study 36413205 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly physical activity levels
Number of subjects: 445
Study 36413205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 445
Study 36413221 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended care (interactive e-learning program based on cognitive behavioral therapy for insomnia)
Number of subjects: 916
Study 36413221 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 916
Study 36413389 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart continence care (SCC) for 3 months
Number of subjects: 160
Study 36413389 — intervention group
Group type: COMPARATOR
Intervention: Regular continence care (RCC)
Number of subjects: 160
Study 36413389 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart continence care (SCC)
Number of subjects: 160
Study 36413390 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based cognitive behavioral therapy (CBT) delivered via a mobile health (mHealth) app for 12 weeks.
Number of subjects: 18
Study 36413390 — intervention group
Group type: COMPARATOR
Intervention: Wait list control condition.
Number of subjects: 18
Study 36413390 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based cognitive behavioral therapy (CBT) delivered via a mobile health (mHealth) app.
Number of subjects: 18
Study 36413408 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically compromised and older individuals
Number of subjects: 0
Study 36413408 — intervention group
Group type: COMPARATOR
Intervention: Young and older trained individuals
Number of subjects: 0
Study 36413418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralesinidase alfa (300 mg)
Number of subjects: 22
Study 36413425 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose heparin
Number of subjects: 1045
Study 36413425 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1045
Study 36413425 — intervention group
Group type: COMPARATOR
Intervention: Heparin started 12 hours before surgery
Number of subjects: 1045
Study 36413425 — intervention group
Group type: COMPARATOR
Intervention: Combined mechanical and pharmacological prophylaxis (enoxaparin)
Number of subjects: 1045
Study 36413436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering treatment or statins
Number of subjects: 0
Study 36413436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36413586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18244
Study 36413586 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18244
Study 36414239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon-based pulmonary vein isolation (PVI) with phrenic nerve injury (PNI)
Number of subjects: 111
Study 36414294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal biomarker derived from AI-based algorithm
Number of subjects: 296
Study 36414294 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning algorithms (logistic regression, k-nearest neighbours, support vector machine, soft voting classifier)
Number of subjects: 296
Study 36414294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal biomarker
Number of subjects: 296
Study 36414316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ramipril/benazepril) and sodium-glucose cotransporter-2 (SGLT2) inhibitors
Number of subjects: 0
Study 36414316 — intervention group
Group type: COMPARATOR
Intervention: No treatment with any of these agents
Number of subjects: 0
Study 36414316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and SGLT2 inhibitor
Number of subjects: 0
Study 36414332 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of new-onset AF in the adult population (≥20 years)
Number of subjects: 411387
Study 36414332 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of AF in the adult population
Number of subjects: 411387
Study 36414332 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalence of AF by sex
Number of subjects: 411387
Study 36414332 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence and prevalence of AF in patients older than 75 years
Number of subjects: 411387
Study 36414332 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted incidence of AF
Number of subjects: 411387
Study 36414425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy (MT), 148 patients (58%) underwent MT
Number of subjects: 254
Study 36414425 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with high NWU, ≥11.4%)
Number of subjects: 254
Study 36414969 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate urinary catheter removal (at the end of surgery)
Number of subjects: 216
Study 36414969 — intervention group
Group type: COMPARATOR
Intervention: Early urinary catheter removal (within 24 hours post-surgery)
Number of subjects: 216